Vericel Corporation(VCEL) Stock Research - Grey Stern Research
Loading...

Vericel Corporation (VCEL) Stock Analysis

$58.38 (0.24%)

VCEL Financial Performance


Use the table below to view Vericel Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $58.24 -
52 Week Low $32.31 -
52 Week High $61.49 -
Market Cap $2.9 Billion 6/21
Gross Margin 72% 10/21
Profit Margin -2% 10/21
EBITDA margin -4% 2/21
Q3 - 2024 Revenue $57.9 Million 2/21
Q3 - 2024 Earnings -$901,000 3/21
Q3 - 2024 Free Cash Flow $41.0 1/21
Trailing 4 Quarters Revenue $226.8 Million 2/21
Trailing 4 Quarters Earnings $3.5 Million 2/21
Quarterly Earnings Growth 75% 3/21
Annual Earnings Growth 119% 1/21
Quarterly Revenue Growth 27% 6/21
Annual Revenue Growth 24% 7/21
Cash On Hand $53.7 Million 16/21
Short Term Debt $6.1 Million 6/21
Long Term Debt $91.3 Million 4/21

Vericel Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Vericel Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 810.21 1/21
PS 12.67 18/21
PB 11.16 2/21
PC 53.55 4/21
Liabilities to Equity 0.52 5/21
ROA 0.01 2/21
ROE 0.01 3/21
Current Ratio 2.94 16/21
Quick Ratio 0.77 20/21
Long Term Debt to Equity 0.35 4/21
Debt to Equity 0.38 3/21
Burn Rate 8.82 3/21
Cash to Cap 0.02 17/21
CCR -45.46 21/21
EV to EBITDA -1183.94 21/21
EV to Revenue 12.87 17/21

Company Details

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

CEO: Mr. Dominick Colangelo

Website: https://vcel.com

Address: 64 Sidney St Cambridge, MASSACHUSETTS

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Vericel Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Vericel Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dyne Therapeutics, Inc. DYN $2.9 Billion
Xencor, Inc. XNCR $1.9 Billion
Blueprint Medicines Corporation BPMC $6.1 Billion
Syndax Pharmaceuticals, Inc. SNDX $1.4 Billion
Cytokinetics, Incorporated CYTK $6.1 Billion
Chimerix, Inc. CMRX $77.4 Million
REGENXBIO Inc. RGNX $460.8 Million
Merus N.V. MRUS $3.2 Billion
CollPlant Biotechnologies Ltd. CLGN $47.3 Million
Crinetics Pharmaceuticals, Inc. CRNX $5.2 Billion
IDEAYA Biosciences, Inc. IDYA $2.3 Billion
Stoke Therapeutics, Inc. STOK $605.4 Million
X4 Pharmaceuticals, Inc. XFOR $63.1 Million
Revolution Medicines, Inc. RVMD $8.1 Billion
Keros Therapeutics, Inc. KROS $2.5 Billion
Pliant Therapeutics, Inc. PLRX $890.3 Million
Relay Therapeutics, Inc. RLAY $734.8 Million
Terns Pharmaceuticals, Inc. TERN $540.2 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Century Therapeutics, Inc. IPSC $131.8 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
VCEL Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 57.9 Million -$901,000
Q2 2024 $ 52.7 Million -$4.7 Million
Q1 2024 $ 51.3 Million -$3.9 Million
Q4 2023 $ 65.0 Million $13.0 Million
Q3 2023 $ 45.6 Million -$3.7 Million
Q2 2023 $ 45.9 Million -$5.0 Million
Q1 2023 $ 41.0 Million -$6.3 Million
Q4 2022 $ 52.7 Million $5.9 Million

View All

VCEL Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $53.7 Million $390.4 Million $97.5 Million $257.5 Million
Q2 2024 $75.9 Million $376.8 Million $95.8 Million $243.0 Million
Q1 2024 $70.7 Million $356.7 Million $92.3 Million $233.9 Million
Q4 2023 $69.1 Million $353.7 Million $88.0 Million $226.0 Million
Q3 2023 $60.5 Million $318.1 Million $85.0 Million $204.4 Million
Q2 2023 $43.0 Million $310.7 Million $83.4 Million $198.9 Million
Q1 2023 $61.8 Million $265.1 Million $46.9 Million $194.0 Million
Q4 2022 $51.1 Million $273.0 Million $47.6 Million $192.3 Million

View All

VCEL Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $41.0 Million $30.8 Million -$5.5 Million
Q2 2024 $1.8 Million -$16.8 Million $5.1 Million
Q1 2024 -$6.8 Million -$14.0 Million -$16.1 Million
Q4 2023 $6.8 Million $0 $6.8 Million
Q3 2023 $7.7 Million $0 $7.7 Million
Q2 2023 $4.9 Million $0 $4.9 Million
Q1 2023 -$1.1 Million -$8.9 Million $10.8 Million
Q4 2022 $5.9 Million -$1.1 Million -$14.1 Million

View All